Tc Biopharm Holdings Plc Quick Ratio (TCBP) starting from the fourth quarter 2024 to fourth quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Tc Biopharm holdings Plc  (TCBP)

Tc Biopharm Holdings Plc's Quick Ratio

TCBP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2024, Quick Ratio deteriorated to 0.22 below Tc Biopharm Holdings Plc's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 141 other companies have achieved higher Quick Ratio than Tc Biopharm Holdings Plc in fourth quarter 2024. While Quick Ratio total ranking in the fourth quarter 2024 has deteriorated compared to the prior quarter from 0 to 2928.

Explain Quick Ratio?
How much Cash & cash equivalents TCBP´s has?
What are TCBP´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/TCBP/financial-strength
https://api.csimarket.com/api/v1/companies/TCBP/fundamentals
https://api.csimarket.com/api/v1/companies/TCBP/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
TCBP Quick Ratio (Dec 31 2024)
Q4
0
Q3
0
Q2
(Mar 31 2024)
Q1
(Dec 31 2023)
Q4
Y / Y Current Liabilities Change -13.49 %
Y / Y Cash & cash equivalent Change -52.2 %
Quick Ratio MRQ 0.22
TCBP's Total Ranking # 2928
Seq. Current Liabilities Change -1.23 %
Seq. Cash & cash equivalent Change -1.45 %



Quick Ratio fourth quarter 2024 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 142
Healthcare Sector # 813
Overall Market # 2928


Quick Ratio Statistics
High Average Low
0.71 0.5 0.29
(Dec 31 2022)   (Mar 31 2024)




Financial Statements
Tc Biopharm Holdings Plc's Current Liabilities $ 7 Millions Visit TCBP's Balance sheet
Tc Biopharm Holdings Plc's Cash & cash equivalent $ 2 Millions Visit TCBP's Balance sheet
Source of TCBP's Sales Visit TCBP's Sales by Geography


Cumulative Tc Biopharm Holdings Plc's Quick Ratio

TCBP's Quick Ratio for the trailling 12 Months

TCBP Quick Ratio

(Dec 31 2024)
12 Months
0
12 Months
0
12 Months
(Mar 31 2024)
12 Months
(Dec 31 2023)
12 Months
Y / Y Current Liabilities TTM Growth -36.31 %
Y / Y Cash & cash equivalent TTM Growth -79.16 %
Quick Ratio TTM 0.2
Total Ranking TTM # 3748
Seq. Current Liabilities TTM Growth -4.1 %
Seq. Cash & cash equivalent TTM Growth -25.47 %


On the trailing twelve months basis In spite of the year on year decrease in TCBP's Current Liabilities to $6.67 millions, cumulative Quick Ratio to 0.2 below the TCBP average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 151 other companies have achieved higher Quick Ratio than Tc Biopharm Holdings Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2024 from 0 to 3748.

Explain Quick Ratio?
How much Cash & cash equivalents TCBP´s has?
What are TCBP´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 152
Healthcare Sector # 952
Within the Market # 3748


trailing twelve months Quick Ratio Statistics
High Average Low
0.71 0.53 0.29
(Dec 31 2022)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Dec 31 2024, within Biotechnology & Pharmaceuticals Industry Quick RatioDec 31 2024 MRQ Cash & cash equivalentDec 31 2024 MRQ Current Liabilities
Alpha Cognition Inc.  0.58 $ 2.808  Millions$ 4.856  Millions
Vivosim Labs Inc   0.56 $ 1.658  Millions$ 2.937  Millions
Amgen Inc   0.52 $ 11,973.000  Millions$ 23,099.000  Millions
Alvotech  0.52 $ 51.428  Millions$ 99.828  Millions
Coherus Oncology inc   0.45 $ 125.987  Millions$ 282.981  Millions
Aim Immunotech Inc   0.43 $ 3.977  Millions$ 9.296  Millions
Elutia Inc   0.40 $ 13.239  Millions$ 33.395  Millions
Silexion Therapeutics Corp  0.35 $ 1.222  Millions$ 3.523  Millions
Ladrx Corporation  0.34 $ 0.760  Millions$ 2.259  Millions
Atara Biotherapeutics Inc   0.32 $ 42.496  Millions$ 134.574  Millions
Windtree Therapeutics Inc  0.31 $ 1.779  Millions$ 5.717  Millions
Vaxart Inc   0.29 $ 26.494  Millions$ 90.878  Millions
Atlantic Coastal Acquisition Corp Ii  0.24 $ 2.916  Millions$ 12.198  Millions
Tc Biopharm holdings Plc  0.22 $ 1.500  Millions$ 6.674  Millions
Xtant Medical Holdings Inc   0.22 $ 6.199  Millions$ 27.809  Millions
Zeo Scientifix Inc   0.21 $ 0.720  Millions$ 3.349  Millions
Bluebird Bio Inc   0.19 $ 62.305  Millions$ 321.462  Millions
Armata Pharmaceuticals Inc   0.19 $ 9.291  Millions$ 48.249  Millions
Agenus Inc  0.18 $ 40.437  Millions$ 221.401  Millions
Champions Oncology Inc   0.16 $ 3.202  Millions$ 19.870  Millions
Tevogen Bio Holdings Inc   0.15 $ 1.283  Millions$ 8.814  Millions
Aptose Biosciences Inc   0.12 $ 0.557  Millions$ 4.459  Millions
Outlook Therapeutics Inc   0.12 $ 5.703  Millions$ 48.237  Millions
Kiromic Biopharma Inc   0.05 $ 1.137  Millions$ 20.904  Millions
Redwoods Acquisition Corp  0.05 $ 0.064  Millions$ 1.248  Millions

Date modified: 2026-10-07T00:41:54+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.